Ac­quired biotech ac­cus­es No­var­tis of let­ting IL-15 as­set 'with­er on the vine'

No­var­tis is be­ing ac­cused of de­lib­er­ate­ly stalling the de­vel­op­ment of an ac­quired IL-15 as­set, cost­ing a small­er biotech up to $940 mil­lion in mile­stone pay­ments …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.